Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Evaxion A/S changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 17 | 19 | +2 |
| Shares | 1.54M | 1.59M | +48.8K (+3.2%) |
| Value | $5.74M | $4.93M | −$805.1K (−14.0%) |
New holders (3)
Institutions that held Evaxion A/S at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| J. Safra Sarasin Holding AG | 22,896 | $71.0K | 0.00% |
| Jane Street Group, LLC | 20,581 | $63.8K | 0.00% |
| UBS Group AG | 6,275 | $19.5K | 0.00% |
Sold out (1)
Institutions that held Evaxion A/S at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| EverSource Wealth Advisors, LLC | 2,266 | $8.43K |